Aegerion Hits New High

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Shares of Aegerion Pharmaceuticals (NASDAQ: AEGR  ) hit a new 52-week high in intra-day trading on Friday. The company hadn't announced any information about its lead drug lomitapide. But a potential competitor from Isis (NASDAQ: IONS  ) and Sanofi (NYSE: SNY  ) received a negative recommendation from a European Medicines Agency committee, citing safety concerns. This bump was temporary, but the EMA info adds to past events to spell trouble for Kynamro -- and a potential win for Aegerion.

So what? 
Lomitapide and Kynamro treat homozygous familial hypercholesterolemia (HoFH) -- or severely high cholesterol. The drugs have run nearly parallel down the pipelines, making an event for one reflect almost immediately upon the other. And the drugs have both proven effective , meaning the final battle panel will play out in the arena of safety.

It's a battle that Kynamro may lose. The drug's latest setback is the EMA committee "nay."  Safety concerns aren't surprising; both drugs have faced safety questions along the way. But a Kynamro-specific concern could become the decider.

Both HoFH drugs went before FDA advisory panels in October, appearing on consecutive days. Aegerion was up first, and shares rose 13% upon the approval recommendation, despite concerns about potential liver risks. Kynamro also received a recommendation, but Isis shares fell 20%,  due to additional concerns raised by its panel. As the Fool's Sean Williams wrote, the panel detailed Kynamro's risk of abnormal tissue growth that appeared in 3.1%  of the trial's patients.

Now what? 
The time for the FDA's decisions is upon us. Aegerion should receive word by the end of this month,  and Isis should come in late January . Investors need to keep a close watch on the results of these decisions.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report, "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2155785, ~/Articles/ArticleHandler.aspx, 10/23/2016 5:54:51 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 day ago Sponsored by:
DOW 18,145.71 -16.64 -0.09%
S&P 500 2,141.16 -0.18 -0.01%
NASD 5,257.40 15.57 0.30%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/21/2016 4:00 PM
AEGR $2.21 Up +0.02 +0.91%
Aegerion Pharmaceu… CAPS Rating: **
IONS $28.07 Down -0.52 -1.82%
Ionis Pharmaceutic… CAPS Rating: *****
SNY $37.75 Down -0.32 -0.84%
Sanofi CAPS Rating: *****